Phase II Study of Erlotinib, a small molecule targeting the epidermal growth factor receptor (EGFR) in the treatment of patients with EGFR-overexpressing 'triple receptor-negative' metastatic carcinoma of the breast that has progressed on Anthracyclines and Taxanes.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Mar 2012 Biomarkers information updated
- 05 Nov 2010 Planned end date changed from 1 Jul 2011 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 05 Nov 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.